EsoCap and LTS Lohmann Therapy-Systeme (LTS) announced the start of cooperation on industrial development of a unique drug delivery technology for diseases of the upper gastrointestinal tract.
This collaboration leverages the collective expertise of a strong partner in the thin film industry with a highly innovative application technology.
EsoCap CEO Isabelle Racamier said: “We are particularly pleased to be partnering with LTS, a global leader in the development and manufacture of film technologies for the pharmaceutical industry.
“We are committed to working closely with LTS to enter rapidly into a clinical trial in patients suffering from eosinophilic esophagitis. EsoCap technology may be beneficial in at least six indications affecting 370 million patients.”
Under the terms of this cooperation, LTS is working on the implementation of its thin-film know-how as applied to EsoCap’s unique drug delivery technology for diseases of the upper gastrointestinal tract.
Senior vice-president of research and development (R&D) at LTS Dr Hanshermann Franke said: “As a company committed to delivering pharmaceutical solutions based on our thin film technology, we are greatly interested in expanding our technology’s fields of application.
“We are thrilled by EsoCap’s highly innovative approach in the area of drug delivery to the upper gastrointestinal tract.”
About EsoCap AG
EsoCap is a Swiss privately funded company based in Basel, Switzerland. The company’s vision is to improve the lives of patients with serious diseases through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.
Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short transit times, with less than two seconds from the mouth to the stomach.
EsoCap owns a unique drug delivery platform, allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.